Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

TRU

TransUnion

Feb 06 • 04:00PM ET

73.48

+3.26 4.64 %

Financial • Financial Data & Stock Exchanges • USA • NYSE

Feb 03, 1:02 PMGartner's disappointing Q4 guidance sparked a sector-wide sell-off, dragging TransUnion shares lower.

Peers: EFX FICO SPGI MSCI PYPL ADBE INTU VRSK MC MORN

| Held by: VTI IJH MOAT VB VO VXF VBR MDY VTV SPMD

Index	-	P/E	34.47	EPS (ttm)	2.13	Insider Own	1.35%	Shs Outstand	194.20M	Perf Week	-7.01%
Market Cap	14.27B	Forward P/E	15.12	EPS next Y	4.86	Insider Trans	-0.69%	Shs Float	191.58M	Perf Month	-12.00%
Enterprise Value	18.80B	PEG	1.15	EPS next Q	1.03	Inst Own	107.87%	Short Float	3.76%	Perf Quarter	-7.70%
Income	420.50M	P/S	3.21	EPS this Y	9.03%	Inst Trans	7.75%	Short Ratio	3.46	Perf Half Y	-18.91%
Sales	4.44B	P/B	3.19	EPS next Y	14.02%	ROA	3.79%	Short Interest	7.21M	Perf YTD	-14.31%
Book/sh	23.04	P/C	18.96	EPS next 5Y	13.10%	ROE	9.68%	52W High	101.19 -27.38%	Perf Year	-23.85%
Cash/sh	3.87	P/FCF	24.22	EPS past 3/5Y	-11.65% -4.38%	ROIC	4.40%	52W Low	65.24 12.64%	Perf 3Y	-0.97%
Dividend Est.	0.46 (0.63%)	EV/EBITDA	12.95	Sales past 3/5Y	12.22% 9.51%	Gross Margin	46.60%	Volatility	6.30% 3.95%	Perf 5Y	-19.10%
Dividend TTM	0.46 (0.63%)	EV/Sales	4.23	EPS Y/Y TTM	86.97%	Oper. Margin	19.99%	ATR (14)	3.37	Perf 10Y	197.01%
Dividend Ex-Date	Nov 21, 2025	Quick Ratio	2.01	Sales Y/Y TTM	8.30%	Profit Margin	9.47%	RSI (14)	38.37	Recom	1.50
Dividend Gr. 3/5Y	5.27% 6.96%	Current Ratio	2.01	EPS Q/Q	41.92%	SMA20	-9.00%	Beta	1.72	Target Price	105.10
Payout	29.05%	Debt/Eq	1.16	Sales Q/Q	7.79%	SMA50	-11.71%	Rel Volume	1.49	Prev Close	70.22
Employees	13400	LT Debt/Eq	1.13	Earnings	Feb 12 BMO	SMA200	-14.31%	Avg Volume	2.08M	Price	73.48
IPO	Jun 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.31% 3.22%	Trades		Volume	3,100,540	Change	4.64%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-25	Resumed	Oppenheimer	Outperform	$93
Oct-01-25	Initiated	Seaport Research Partners	Neutral
Sep-03-25	Upgrade	Needham	Hold → Buy
Jul-10-25	Initiated	BMO Capital Markets	Outperform	$115
Apr-10-25	Resumed	BofA Securities	Underperform	$84
Oct-10-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$130
Oct-01-24	Initiated	UBS	Neutral	$110
Aug-28-24	Downgrade	Needham	Buy → Hold
Aug-13-24	Initiated	Wells Fargo	Overweight	$100
Jul-09-24	Initiated	Wolfe Research	Peer Perform
Jun-20-24	Upgrade	BofA Securities	Neutral → Buy	$92
Apr-01-24	Upgrade	BofA Securities	Underperform → Neutral	$65 → $90
Dec-19-23	Initiated	Oppenheimer	Outperform	$81
Oct-25-23	Downgrade	Evercore ISI	Outperform → In-line
Oct-25-23	Downgrade	BofA Securities	Buy → Underperform	$95 → $44
Apr-26-23	Upgrade	Needham	Hold → Buy	$84
Mar-01-23	Upgrade	Exane BNP Paribas	Neutral → Outperform	$80
Feb-01-23	Upgrade	BofA Securities	Neutral → Buy	$72 → $91
Jan-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$70 → $88
Jan-06-23	Initiated	Exane BNP Paribas	Neutral	$64.50

Show Previous Ratings

Feb-06-26 07:39PM	Analyst Report: Equifax Inc. (Morningstar Research)
02:02PM	Pre-Q4 Earnings: Should Spotify Stock be in Your Portfolio? (Zacks)
11:28AM	S&P Global Gears Up to Report Q4 Earnings: What's in Store? (Zacks)
07:33AM	Dive Deposits: CFPB tamps down on complaint portal (Banking Dive)
Feb-05-26 10:00AM	TransUnion (TRU) Earnings Expected to Grow: Should You Buy? (Zacks)
08:53AM	Loading…
08:53AM	Software ate the world. Now, Wall Street is worried AI will eat software. (MarketWatch)
Feb-04-26 01:58PM	Analyst Report: Equifax Inc. (Morningstar Research)
Feb-03-26 07:59PM	Analyst Report: Equifax Inc. (Morningstar Research) -12.47%
01:00PM	Analyst Report: TransUnion (Morningstar Research)
08:07AM	High Purchase Intent Points to Increased Vehicle Sales and Growing Used-Car Supply (GlobeNewswire)
Feb-02-26 07:07AM	TransUnion Announces Definitive Agreement to Acquire Mobile Division of RealNetworks to Enhance Voice and Messaging Solutions (GlobeNewswire)
Feb-01-26 11:02PM	3 Reasons TRU is Risky and 1 Stock to Buy Instead (StockStory)
Jan-30-26 01:15PM	Gartner Gears Up to Report Q4 Earnings: What's in the Offing? (Zacks)
12:01PM	4 Business Services Firms Poised to Beat Estimates This Earnings Season (Zacks)
09:40AM	TransUnion (TRU) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
12:10PM	Loading…
Jan-28-26 12:10PM	Will TransUnion (TRU) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:00AM	Juniper Research Names TransUnion Gold Winner in Best Branded Call Solution in Telco Innovation Category (GlobeNewswire)
06:00AM	TransUnion and Zenbase Bring Rental Payment Information to Credit Reports (GlobeNewswire)
06:00AM	TransUnion and FrontLobby to Launch Rental Payment Reporting on Credit Files (GlobeNewswire)
Jan-23-26 08:47AM	TransUnion (TRU): Vulcan Value Partners Journey from Observation to Investment (Insider Monkey)
Jan-15-26 12:25PM	Financial Services Roundup: Market Talk (The Wall Street Journal)
10:13AM	Young gig workers are selling or renting their profiles for extra income, report finds (Yahoo Finance)
08:00AM	Nearly One in Three Millennial and Gen Z Gig Workers Rent Their Gig Platform Accounts to Unverified Users (GlobeNewswire)
Jan-14-26 08:00AM	TransUnion and Actable Prove AI Success Starts with Data: Partnership Delivers 10% Lift in Predictive Modeling (GlobeNewswire)
06:00AM	Your personal finance to-do list for 2026, broken down month by month (Yahoo Finance)
Jan-13-26 06:50AM	TransUnion Announces Earnings Release Date for Fourth Quarter 2025 Results (GlobeNewswire)
06:00AM	Canadians' Financial Outlook Divided as Inflation and Recession Fears Appear to Shape Behaviours - TransUnion Canada Study (GlobeNewswire)
Jan-11-26 11:15AM	A 2025 security breach exposed over 184 million private passwords. How to stay safe while you browse (Moneywise)
Jan-08-26 04:15PM	TransUnion's 2026 Mortgage Pricing Goes Live - Prioritizing Lower Costs for Homebuyers (GlobeNewswire)
10:02AM	Trump Wants to Lower Housing Costs. How Fair Isaac and Equifax Stock Could Benefit. (Barrons.com)
04:34PM	Loading…
Jan-06-26 04:34PM	S&P 500 and Dow Rally to Record Highs as Tech Stocks Surge (Barchart)
03:05PM	Why TransUnion (TRU) Shares Are Trading Lower Today (StockStory)
11:57AM	Equifax, TransUnion Shares Fall as Pulte Targets Credit Pricing (Bloomberg)
10:53AM	Analyst Report: TransUnion (Morningstar Research)
10:52AM	Analyst Report: Equifax Inc. (Morningstar Research)
08:16AM	Equifax, TransUnion stocks fall after FHFA criticism on pricing (Investing.com)
Jan-05-26 07:01PM	Credit card interest rate forecast for 2026: Rate cuts will bring little relief to cardholders (Bankrate)
11:16AM	5 smart moves to raise your credit score ASAP - and get better loan rates in 2026 (MarketWatch)
08:00AM	TransUnion Appoints Francesca Noli Executive Vice President of Global Consumer Solutions (GlobeNewswire)
Dec-31-25 09:50AM	Why TransUnion (TRU) is a Top Momentum Stock for the Long-Term (Zacks)
Dec-30-25 02:15PM	Judge boots Georgia tenant out of home after not paying $13K in rent, buying luxury items instead. How did this happen? (Moneywise)
Dec-29-25 11:31AM	Reasons Why You Should Hold TransUnion Stock in Your Portfolio (Zacks)
Dec-27-25 08:00AM	Reporting rent can boost your credit, but 1 tiny mistake could cost you all the benefits (Moneywise)
Dec-23-25 06:20AM	TransUnion Appoints Sayan Chakraborty and Charlotte Yarkoni to its Board of Directors (GlobeNewswire)
Dec-19-25 11:10AM	JPMorgan Highlights 11 Tech Stocks for 2026 (GuruFocus.com)
Dec-18-25 02:42PM	Analyst Report: TransUnion (Morningstar Research)
Dec-17-25 12:15PM	Paychex Gears Up to Report Q2 Earnings: What's in Store? (Zacks)
Dec-15-25 06:06AM	Car-loan delinquencies will see little movement in 2026: TransUnion (Wards Auto)
Dec-10-25 04:09PM	The Fed just cut interest rates again. We asked 5 experts what Americans should do next (Bankrate)
10:17AM	Credit card balances projected to tick up by smallest amount in years in 2026 (Yahoo Finance)
08:17AM	TransUnion 2026 Outlook: Moderate Credit Card Balance Growth and Stable Delinquency Rates Signal Consumer Perseverance (GlobeNewswire)
Dec-09-25 08:17AM	TransUnion Unveils Enhancements to Next-Generation Device Risk Solution to Combat Rising Fraud Losses (GlobeNewswire)
Dec-08-25 04:57PM	Analyst Report: TransUnion (Morningstar Research)
Dec-04-25 08:17AM	Student Loan Delinquencies Among Renters Double in Early 2025 (GlobeNewswire)
Dec-02-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Dec-01-25 08:00AM	National CineMedia and TransUnion Partner to Bring Cinema into Cross-Channel Attribution (Business Wire)
Nov-28-25 12:16PM	Here's Why Investors Should Retain TransUnion Stock for Now (Zacks)
11:30AM	Why Is Verisk (VRSK) Up 2.9% Since Last Earnings Report? (Zacks)
Nov-25-25 04:00AM	Canadians Take on More Credit Amid Lower Interest Rates as Mortgage Churn Rises and Economic Disparities Deepen (GlobeNewswire)
Nov-20-25 08:00AM	Higher Credit Card Usage Expected Among U.S. Shoppers this Holiday Shopping Season (GlobeNewswire)
Nov-19-25 07:17AM	TransUnion Named a Leader in the 2025 Gartner Magic Quadrant for Marketing Mix Modeling Solutions (GlobeNewswire)
04:30AM	Hong Kong lenders tread carefully amid mixed recovery signs, TransUnion says (South China Morning Post)
Nov-18-25 08:17AM	TransUnion and Snappt Collaborate to Improve Efficiency in Multifamily Leasing (GlobeNewswire)
Nov-17-25 11:17AM	Jacobs Gears Up to Report Q4 Earnings: Key Factors to Note (Zacks)
Nov-13-25 10:34PM	Q3 Earnings Roundup: TransUnion (NYSE:TRU) And The Rest Of The Data & Business Process Services Segment (StockStory)
01:15PM	Is APP Stock Still a Smart Buy After Its Strong Q3 Earnings? (Zacks)
08:00AM	TransUnion Responds to Growing Challenge of Credit Washing with Pioneering Fraud Detection Solution (GlobeNewswire)
Nov-11-25 08:00AM	Auto and Property Insurers Will Need to Maximize Retention Efforts to Stay Competitive in 2026 (GlobeNewswire)
Nov-07-25 11:55AM	Insperity Stock Declines 23% After Reporting Q3 Earnings Miss (Zacks)
06:50AM	TransUnion Declares Third Quarter 2025 Dividend of $0.115 per Share (GlobeNewswire)
Nov-06-25 01:14PM	Jenga Tower US Economy Teeters as Middle Class Pulls Back Spending (Bloomberg)
12:38PM	GDOT Gears Up to Report Q3 Earnings: Here's What You Should Know (Zacks)
12:33PM	Mogo Set to Report Q3 Earnings: Here's What Investors Should Know (Zacks)
Nov-04-25 06:50AM	TransUnion to Present at Upcoming Investor Conferences in Chicago and New York (GlobeNewswire)
Nov-03-25 11:37AM	More consumers are slipping into the riskiest credit segment (Yahoo Finance)
08:00AM	TransUnion Report Reveals Diverging Credit Risk Trends Among U.S. Consumers (GlobeNewswire)
03:45AM	Is TransCrypts Riding the Next Wave of AI Infrastructure? 3 Reasons Tech Investors Will Want to Keep an Eye on This Startup. (Motley Fool)
Nov-01-25 06:30AM	Is Your Credit Report Protected From Medical Debt (Money Digest)
Oct-31-25 09:00PM	A Fight Over Credit Scores Turns Into All-Out War (The Wall Street Journal)
01:46PM	Republic Services Earnings Surpass Estimates in Q3, Revenues Miss (Zacks)
Oct-30-25 01:06PM	S&P Global Q3 Earnings & Revenues Outpace Estimates, Increase Y/Y (Zacks)
01:36AM	The 5 Most Interesting Analyst Questions From TransUnion's Q3 Earnings Call (StockStory)
Oct-29-25 03:42PM	What a Federal Reserve rate cut means for your finances (Associated Press Finance)
12:34PM	Fiserv Q3 Earnings Miss Estimates, Revenues Decline 6% Y/Y (Zacks)
Oct-28-25 01:13PM	TransUnion Stock Gains 6% Post Reporting Q3 Earnings & Revenue Beat (Zacks)
Oct-27-25 07:42AM	Auto lenders are on the lookout for credit washing scams (Wards Auto)
05:30AM	Hong Kong businesses lose US$11 billion to digital fraud in past year, TransUnion says (South China Morning Post)
Oct-24-25 09:45AM	TRU Q3 Deep Dive: Tech Modernization, Mortgage Changes, and International Growth Shape Outlook (StockStory)
08:55AM	Morning Movers: Tesla, IBM slipping following quarterly reports (TipRanks)
Oct-23-25 05:15PM	Analyst Report: TransUnion (Morningstar Research)
05:00PM	TransUnion (TRU) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
04:34PM	Earnings live: Intel stock surges, Ford rises after-hours, Deckers drops (Yahoo Finance)
09:30AM	TransUnion (TRU) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:09AM	Earnings live: Tesla stock falls after earnings miss, American Airlines climbs, IBM and Hasbro sink (Yahoo Finance)
07:30AM	TransUnion (TRU) Tops Q3 Earnings and Revenue Estimates (Zacks)
06:39AM	TransUnion's (NYSE:TRU) Q3: Beats On Revenue (StockStory)
06:26AM	TransUnion: Q3 Earnings Snapshot (Associated Press Finance)
06:18AM	TransUnion Announces Strong Third Quarter 2025 Results, Exceeding All Key Financial Metrics (GlobeNewswire)
Oct-22-25 04:35PM	Earnings live: Tesla stock falls after earnings miss, IBM sinks (Yahoo Finance)
09:21AM	TransUnion (TRU) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)

TransUnion engages in the provision of information and risk management solutions. It also provides consumer reports, risk scores, analytical services, and decision-making capabilities to businesses. It operates through the following segments: U.S. Markets, International, and Corporate. The U.S. Markets segment provides consumer reports, risk scores, analytical services, and decision-making capabilities to businesses. The International segment provides credit reports, analytics and decision-making services and other value-added risk management services. The Corporate segment provides support services to each segment, holds investments, and conducts enterprise functions. The company was founded in 1968 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Skinner Todd C.	President, International	Feb 02 '26	Sale	78.79	500	39,395	31,725	Feb 03 05:35 PM
Skinner Todd C.	Officer	Feb 02 '26	Proposed Sale	78.79	500	39,395		Feb 02 10:55 AM
Skinner Todd C.	President, International	Jan 02 '26	Sale	85.71	500	42,855	32,225	Jan 05 04:53 PM
CHAOUKI STEVEN M	President, US Markets	Jan 02 '26	Sale	85.71	1,000	85,710	61,592	Jan 05 04:52 PM
Skinner Todd C.	Officer	Jan 02 '26	Proposed Sale	85.71	500	42,855		Jan 02 11:51 AM
CHAOUKI STEVEN M	Officer	Jan 02 '26	Proposed Sale	85.71	1,000	85,710		Jan 02 09:51 AM
Chambers Tiffani	EVP, Chief Operations Officer	Dec 17 '25	Sale	86.00	4,318	371,348	50,427	Dec 19 04:07 PM
Chambers Tiffani	Officer	Dec 17 '25	Proposed Sale	86.00	4,318	371,348		Dec 17 10:25 AM
Skinner Todd C.	President, International	Dec 10 '25	Sale	81.07	500	40,535	32,652	Dec 11 05:16 PM
Skinner Todd C.	Officer	Dec 10 '25	Proposed Sale	81.07	500	40,535		Dec 10 10:30 AM
CHAOUKI STEVEN M	President, US Markets	Dec 01 '25	Sale	84.04	1,000	84,040	62,592	Dec 02 07:22 PM
CHAOUKI STEVEN M	Officer	Dec 01 '25	Proposed Sale	84.04	1,000	84,040		Dec 01 11:47 AM
CHAOUKI STEVEN M	President, US Markets	Nov 03 '25	Sale	80.47	1,000	80,470	63,592	Nov 04 04:42 PM
CHAOUKI STEVEN M	Officer	Nov 03 '25	Proposed Sale	80.47	1,000	80,470		Nov 03 10:45 AM
CHAOUKI STEVEN M	President, US Markets	Oct 01 '25	Sale	83.19	1,000	83,190	64,592	Oct 03 05:39 PM
CHAOUKI STEVEN M	Officer	Oct 01 '25	Proposed Sale	83.19	1,000	83,190		Oct 01 11:03 AM
RUSSELL HEATHER J	EVP, Chief Legal Officer	Sep 05 '25	Sale	90.01	5,337	480,383	23,011	Sep 08 06:22 PM
RUSSELL HEATHER J	Officer	Sep 05 '25	Proposed Sale	90.01	5,337	480,383		Sep 05 10:56 AM
CHAOUKI STEVEN M	President, US Markets	Sep 02 '25	Sale	86.12	1,000	86,120	65,592	Sep 03 05:25 PM
Williams Jennifer A.	SVP, Chief Accounting Officer	Aug 29 '25	Sale	88.46	755	66,787	5,691	Sep 02 05:56 PM
CHAOUKI STEVEN M	Officer	Sep 02 '25	Proposed Sale	86.12	1,000	86,120		Sep 02 11:23 AM
Williams Jennifer A.	SVP, Chief Accounting Officer	Aug 26 '25	Sale	89.22	245	21,859	6,761	Aug 27 04:59 PM
CHAOUKI STEVEN M	President, US Markets	Aug 08 '25	Sale	91.21	1,000	91,210	73,393	Aug 11 05:51 PM
CHAOUKI STEVEN M	Officer	Aug 08 '25	Proposed Sale	91.21	1,000	91,210		Aug 08 10:04 AM
Williams Jennifer A.	SVP, Chief Accounting Officer	Aug 04 '25	Sale	92.89	972	90,289	7,108	Aug 06 04:35 PM
CHAOUKI STEVEN M	President, US Markets	Jul 01 '25	Sale	87.14	1,000	87,140	74,393	Jul 02 05:15 PM
CHAOUKI STEVEN M	Officer	Jul 01 '25	Proposed Sale	87.14	1,000	87,140		Jul 01 11:10 AM
CHAOUKI STEVEN M	President, US Markets	Jun 02 '25	Sale	84.91	1,000	84,910	75,393	Jun 03 05:31 PM
Martin Timothy J	Officer	Jun 02 '25	Proposed Sale	84.91	2,500	212,275		Jun 02 12:32 PM
CHAOUKI STEVEN M	Officer	Jun 02 '25	Proposed Sale	84.91	1,000	84,910		Jun 02 09:39 AM
CHAOUKI STEVEN M	President, US Markets	May 01 '25	Sale	82.96	1,000	82,960	76,393	May 02 04:29 PM
Martin Timothy J	Officer	May 01 '25	Proposed Sale	82.96	2,500	207,400		May 01 09:55 AM
CHAOUKI STEVEN M	Officer	May 01 '25	Proposed Sale	82.96	1,000	82,960		May 01 09:39 AM
CHAOUKI STEVEN M	President, US Markets	Apr 01 '25	Sale	83.31	1,000	83,310	77,393	Apr 03 06:37 PM
Martin Timothy J	Officer	Apr 01 '25	Proposed Sale	83.31	2,500	208,275		Apr 01 10:25 AM
CHAOUKI STEVEN M	Officer	Apr 01 '25	Proposed Sale	83.31	1,000	83,310		Apr 01 10:16 AM
Martin Timothy J	EVP - Global Solutions	Mar 06 '25	Sale	88.64	2,500	221,600	48,510	Mar 10 05:50 PM
Martin Timothy J	Officer	Mar 06 '25	Proposed Sale	88.64	2,500	221,600		Mar 06 11:21 AM
CHAOUKI STEVEN M	President, US Markets	Mar 03 '25	Sale	91.98	1,000	91,980	78,393	Mar 04 06:53 PM
Achanta Venkat	EVP, Chief Tech, Data & Analy.	Mar 03 '25	Sale	91.98	13,163	1,210,733	104,295	Mar 04 06:51 PM
Achanta Venkat	Officer	Mar 03 '25	Proposed Sale	91.98	13,163	1,210,733		Mar 03 01:37 PM
CHAOUKI STEVEN M	Officer	Mar 03 '25	Proposed Sale	91.98	1,000	91,980		Mar 03 10:16 AM
Williams Jennifer A.	SVP, Chief Accounting Officer	Feb 26 '25	Sale	95.74	200	19,148	7,186	Feb 27 07:56 PM
Achanta Venkat	EVP, Chief Tech, Data & Analy.	Feb 26 '25	Sale	95.74	1,821	174,343	105,443	Feb 27 07:53 PM
Achanta Venkat	Officer	Feb 26 '25	Proposed Sale	95.74	1,821	174,343		Feb 26 12:36 PM

Open in Screener

MAIA

MAIA Biotechnology Inc

Feb 06 • 04:00PM ET

1.97

+0.06 3.14 %

Healthcare • Biotechnology • USA • AMEX

MAIA MAIA Biotechnology Inc daily Stock Chart

Peers: PDSB FATE AVXL IONS AFMD PTGX ONCT BCLI ADMA VSTM

Index	-	P/E	-	EPS (ttm)	-0.74	Insider Own	23.64%	Shs Outstand	34.45M	Perf Week	-18.26%
Market Cap	72.95M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	4.76%	Shs Float	28.28M	Perf Month	20.86%
Enterprise Value	62.06M	PEG	-	EPS next Q	-0.13	Inst Own	6.70%	Short Float	5.77%	Perf Quarter	74.34%
Income	-22.34M	P/S	-	EPS this Y	50.17%	Inst Trans	1.02%	Short Ratio	1.88	Perf Half Y	33.11%
Sales	0.00M	P/B	1628.10	EPS next Y	6.76%	ROA	-212.50%	Short Interest	1.63M	Perf YTD	28.76%
Book/sh	0.00	P/C	6.70	EPS next 5Y	-	ROE	-2691.06%	52W High	3.19 -38.24%	Perf Year	-6.19%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	3.77% -11.40%	ROIC	-53610.15%	52W Low	0.87 126.44%	Perf 3Y	-56.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.61% 12.81%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	44.50%	Oper. Margin	-	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.18	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.44	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.18	EPS Q/Q	-134.24%	SMA20	-6.94%	Beta	0.06	Target Price	14.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	19.34%	Rel Volume	0.63	Prev Close	1.91
Employees	13	LT Debt/Eq	0.00	Earnings	Nov 04	SMA200	20.90%	Avg Volume	867.59K	Price	1.97
IPO	Jul 28, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	542,905	Change	3.14%

Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire) -10.75%
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire) -5.76%
Jan-20-26 10:15AM	MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum (GlobeNewswire) +26.44%
Dec-24-25 08:01AM	MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings (GlobeNewswire) +8.82%
Dec-16-25 04:15PM	MAIA Biotechnology Announces $1.51 Million Private Placement (GlobeNewswire) -8.89% -6.50%
01:00PM	Loading…
Dec-11-25 01:00PM	MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates (GlobeNewswire) +18.84%
09:00AM	MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer (GlobeNewswire)
08:00AM	MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential (GlobeNewswire)
Dec-10-25 02:00PM	MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach (GlobeNewswire)
Dec-01-25 09:17AM	MAIA Biotechnology Announces Open Market Purchases by CEO and Directors (GlobeNewswire)
Nov-21-25 09:01AM	MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025 (GlobeNewswire)
Nov-20-25 08:47AM	MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania's 2025 Smart Diaspora Conference on Oncology Research and Innovation (GlobeNewswire) -5.33%
Oct-27-25 10:45AM	MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-23-25 08:36AM	MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +7.35%
Oct-13-25 04:20PM	MAIA Biotechnology Announces $736,600 Private Placement (GlobeNewswire) -6.37%
03:13PM	Loading…
Oct-07-25 03:13PM	Cancer drug maker takes sudden pivot into crypto (TheStreet)
08:47AM	MAIA Biotechnology to Initiate Digital Asset Treasury Strategy Focused on Top-Tier Crypto Assets (GlobeNewswire)
Sep-29-25 04:30PM	MAIA Biotechnology Announces $2.25 Million Private Placement (GlobeNewswire)
Sep-24-25 08:01AM	MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent (GlobeNewswire)
Sep-12-25 08:33AM	Maias NSCLC immunotherapy secures Phase II efficacy win (Clinical Trials Arena)
Sep-11-25 09:27AM	MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +8.97%
Sep-05-25 09:03AM	MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer (GlobeNewswire)
Aug-27-25 09:01AM	MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells (GlobeNewswire) +7.14%
Aug-18-25 08:00AM	Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) (GlobeNewswire)
Aug-13-25 09:01AM	MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy (GlobeNewswire)
Jul-28-25 08:01AM	MAIA Biotechnology Receives FDAs Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer (Business Wire)
Jul-17-25 09:17AM	MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy (Business Wire)
Jul-10-25 10:40AM	MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial (Clinical Trials Arena)
Jul-09-25 09:15AM	MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer (Business Wire) +9.24%
Jul-01-25 09:00AM	MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress (Business Wire) +6.67%
08:15AM	Loading…
Jun-24-25 08:15AM	MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board (Business Wire)
Jun-19-25 09:25AM	MAIA Biotechnology, Roche sign supply agreement for cancer therapies (TipRanks)
Jun-18-25 09:15AM	MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies (Business Wire) +8.43%
Jun-10-25 08:46AM	MAIA Biotechnology to Present at BIO International Convention 2025 (Business Wire)
Jun-05-25 02:28PM	MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients (Benzinga) +10.80%
11:10AM	MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial (Business Wire)
08:04AM	MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer (Business Wire)
May-27-25 08:29PM	MAIA Biotechnology, Inc. (MAIA) Raises $695K in Private Placement to Advance Cancer Trial (Insider Monkey)
05:35PM	CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000 (Business Wire)
May-15-25 11:05AM	MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting (Business Wire)
May-14-25 10:15AM	MAIA Biotechnology Announces Director Participation in Recent Private Placement (Business Wire)
May-06-25 10:00AM	Best Momentum Stocks to Buy for May 6th (Zacks) +7.85%
07:41AM	New Strong Buy Stocks for May 6th (Zacks)
May-05-25 11:45PM	CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement (Business Wire) -6.83%
04:05PM	MAIA Biotechnology Announces $1.08 Million Private Placement (Business Wire)
Apr-01-25 08:30AM	MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders (Business Wire)
Mar-28-25 10:39AM	Is MAIA Biotechnology, Inc. (MAIA)he Cheapest Stock Insiders Are Buying In March? (Insider Monkey)
Mar-27-25 12:00PM	MAIA Biotechnology, Inc. (MAIA) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-25-25 08:46AM	MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 (Business Wire) -5.99%
Mar-20-25 09:20AM	MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug (Business Wire)
Mar-19-25 11:00AM	MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO (Business Wire)
Feb-27-25 08:51AM	MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients (Business Wire) +7.07%
Feb-26-25 08:47AM	MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer (Business Wire) +5.75%
Feb-24-25 04:30PM	MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million (Business Wire)
Feb-18-25 03:44PM	MAIA Biotechnology Announces Private Placement of $2,715,000 (Business Wire)
Feb-04-25 08:51AM	MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer (Business Wire) +5.82%
Jan-10-25 09:45AM	MAIA Biotechnology to Present at Biotech Showcase 2025 (Business Wire)
Jan-07-25 09:12AM	MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications (Business Wire) +15.53%
Dec-19-24 08:47AM	MAIA Biotechnology Announces Director Participation in Recent Private Placement Closings (Business Wire) +5.15%
Dec-16-24 08:37AM	MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas (Business Wire) +10.00%
Dec-09-24 06:00PM	MAIA Biotechnology Announces Private Placement of Approximately $950,000 (Business Wire)
Dec-03-24 08:17AM	MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer (Business Wire)
Nov-07-24 08:47AM	MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement (Business Wire)
Nov-05-24 09:45AM	MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (Business Wire) +6.25%
Oct-28-24 07:00PM	MAIA Biotechnology Announces $2.44 Million Private Placement (Business Wire) +8.37%
Oct-15-24 08:15AM	MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics (Business Wire)
Sep-10-24 06:00AM	MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer (Business Wire) -5.75%
Sep-04-24 08:30AM	MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) +15.75%
Jul-23-24 04:11AM	MAIA Biotechnology Announces New Updates from Phase 2 Trial of Novel Cancer Treatment Agent (Business Wire)
Jun-07-24 12:31PM	MAIA Biotechnology's Telomere Targeting Functionality is Shown Viable by FDAs Approval of a Telomerase Inhibitor Agent Therapy (Business Wire) +16.27%
Jun-06-24 10:07AM	MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent (Business Wire)
Jun-04-24 08:41AM	MAIA Biotechnology Reveals New Clinical Data Showing THIOs Strong Efficacy in Non-Small Cell Lung Cancer (Business Wire) -26.27%
May-17-24 08:37AM	MAIA Biotechnology to Present at the BIO International Convention 2024 (Business Wire) +6.09%
May-16-24 08:37AM	MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting (Business Wire) +8.71%
Apr-30-24 08:08AM	MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement (Business Wire) -8.72%
Apr-29-24 08:08AM	MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement (Business Wire) +9.18%
Apr-23-24 08:51AM	MAIA Biotechnology Announces $1.00 Million Private Placement (Business Wire) +8.85%
Apr-05-24 08:01AM	MAIA Biotechnology to Present at Two Investor Conferences in April 2024 (Business Wire) +6.82%
Mar-28-24 03:00PM	MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero (Business Wire) -11.29%
Mar-26-24 03:00PM	MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement (Business Wire)
08:01AM	MAIA Biotechnology Announces $1.33 Million Private Placement (Business Wire)
Mar-22-24 03:00PM	MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement (Business Wire) +8.76%
Mar-21-24 03:00PM	MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board (Business Wire) +17.58%
Mar-16-24 01:49AM	Director Ngar Louie Acquires 170,940 Shares of MAIA Biotechnology Inc (MAIA) (GuruFocus.com)
Mar-07-24 09:45AM	MAIA Biotechnology to Participate in the 36th Annual ROTH Conference (Business Wire)
Mar-06-24 11:04AM	MAIA Biotechnology and Nationwide Childrens Hospital Announce Presentation of THIOs Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting (Business Wire)
08:48AM	MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients (Business Wire)
Mar-05-24 08:45AM	MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders (Business Wire)
Feb-27-24 10:30AM	MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor (GlobeNewswire)
Feb-22-24 10:30AM	MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer (GlobeNewswire)
Feb-07-24 08:01AM	MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer (Business Wire)
Jan-24-24 07:15AM	MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds (Business Wire)
Jan-17-24 09:00AM	MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024 (Business Wire) +20.33%
Jan-05-24 08:00AM	MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024 (Business Wire) +26.89%
Dec-19-23 07:00AM	MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer (Business Wire)
Dec-01-23 09:55AM	Bears are Losing Control Over MAIA Biotechnology, Inc. (MAIA), Here's Why It's a 'Buy' Now (Zacks)
Nov-17-23 03:52PM	MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering (Business Wire) -13.57%
09:00AM	MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer (ACCESSWIRE)
Nov-15-23 09:35AM	MAIA Biotechnology Announces $4 Million Registered Direct Offering (Business Wire) -24.73%
Nov-10-23 07:01AM	FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma (Business Wire)

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Stan	Director	Dec 22 '25	Buy	1.22	57,189	69,999	1,421,478	Dec 23 08:18 AM
CHAOUKI STEVEN M	Director	Dec 22 '25	Buy	1.22	40,849	49,999	151,873	Dec 23 08:16 AM
Louie Ngar Yee	Director	Dec 22 '25	Buy	1.22	81,699	100,000	1,248,888	Dec 23 08:14 AM
Smith Stan	Director	Dec 05 '25	Buy	1.20	13,740	16,441	4,580	Dec 09 04:51 PM
Vitoc Vlad	Chief Executive Officer	Nov 28 '25	Buy	1.14	50,000	56,830	881,421	Dec 01 06:20 AM
Vitoc Vlad	Chief Executive Officer	Nov 26 '25	Buy	1.05	22,000	23,019	853,421	Dec 01 06:20 AM
Luput Cristian	Director	Nov 26 '25	Buy	1.08	20,000	21,616	419,483	Dec 01 06:18 AM
Luput Cristian	Director	Nov 28 '25	Buy	1.11	18,145	20,230	437,628	Dec 01 06:18 AM
Smith Stan	Director	Nov 26 '25	Buy	1.04	15,000	15,582	1,364,289	Dec 01 06:14 AM
Luput Cristian	Director	Nov 25 '25	Buy	0.98	10,000	9,785	399,483	Nov 28 06:52 AM
Vitoc Vlad	Chief Executive Officer	Nov 25 '25	Buy	0.97	10,500	10,144	831,421	Nov 28 06:48 AM
Smith Stan	Director	Nov 25 '25	Buy	0.98	15,000	14,700	1,349,289	Nov 26 04:43 PM
Smith Stan	Director	Nov 24 '25	Buy	0.99	10,000	9,900	1,334,289	Nov 26 04:43 PM
Vitoc Vlad	Chief Executive Officer	Nov 24 '25	Buy	0.99	10,000	9,891	820,921	Nov 25 04:15 PM
Vitoc Vlad	Chief Executive Officer	Nov 21 '25	Buy	0.92	1,800	1,656	810,921	Nov 25 04:15 PM
Smith Stan	Director	Oct 01 '25	Buy	1.30	19,230	24,999	1,324,289	Oct 02 04:51 PM
Smith Stan	Director	Jun 03 '25	Buy	1.50	33,333	50,000	1,305,059	Jun 05 04:42 PM
Guerrero Ramiro	Director	May 08 '25	Buy	1.50	20,000	30,000	588,218	May 12 04:14 PM
Smith Stan	Director	May 08 '25	Buy	1.50	66,666	99,999	1,271,726	May 12 04:12 PM
Guerrero Ramiro	Director	Mar 03 '25	Buy	1.50	33,333	50,000	568,218	Mar 05 04:42 PM
Smith Stan	Director	Mar 03 '25	Buy	1.50	25,000	37,500	1,205,060	Mar 05 04:40 PM
Guerrero Ramiro	Director	Feb 24 '25	Buy	1.50	73,333	110,000	534,885	Feb 25 04:11 PM
Smith Stan	Director	Feb 24 '25	Buy	1.50	50,000	75,000	1,180,060	Feb 25 04:10 PM

TRU

TransUnion

MAIA

MAIA Biotechnology Inc

Upgrade your FINVIZ experience